Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Transplantation. 2015 Apr;99(4):668–677. doi: 10.1097/TP.0000000000000561

Figure 6. Anti-heparanase and PI3K activator inhibit down-regulation of CCL21 in contact hypersensitivity.

Figure 6

Thirty six hours after DNFB challenge or vehicle application, the ears were treated with anti-heparanase Ab (1μg/ear) or PI3K activator (10μg/ear) or PBS. Additional 12 hours later the ear skin sheets were stained for LYVE-1 (Cy3), CCL21 (Dye Light 488), and heparan sulfate (HS, Alexa Fluor 647). Original magnification 200×. Bar, 100μm. Representative images from 2 mice/group, 3 independent experiments.